SCHEMBL3098010

SCHEMBL3098010

COc1ccc(C(=O)C(c2ccc(OC)cc2)C(C(=O)O)C(=O)C2CCN(C(=O)OCc3ccccc3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.53
CHRM1 P11229 1/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
CYP2C19 P33261 1/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
HTT P42858 1/20 0.48
MMP1 P03956 2/20 0.47
MMP3 P08254 2/20 0.47
MMP7 P09237 2/20 0.47
MMP9 P14780 2/20 0.47
MMP2 P08253 1/20 0.47
MMP8 P22894 1/20 0.47
GRIN2B Q13224 2/20 0.45
MMP13 P45452 1/20 0.42
GAA P10253 1/20 0.42
ENPP2 Q13822 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3098279 0.91 CHRM2 (0.50) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL3099573 0.81 CHRM2 (0.54) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL3108038 0.81 CHRM2 (0.54) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL3097183 0.79 NPSR1 (0.52) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL27763127 0.79 CHRM2 (0.51) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL3104965 0.79 NPSR1 (0.52) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL3088679 0.78 CHRM2 (0.51) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL3105503 0.77 CHRM2 (0.50) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL22589174 0.77 SMN1; SMN2 (0.46) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1
SCHEMBL3097695 0.77 SMN1; SMN2 (0.61) CHRM2CHRM1SMN1; SMN2CYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 US disclosed
EP-2009006-A1 UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES TORAY INDUSTRIES, INC. (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF UROD, UTS2R, SLC14A1 CHRM2 2218/4885CHRM1 3470/4885SMN1; SMN2 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.